Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Zillow Group Inc Class C (Z) Price & Performance

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.

Zillow Group (Z) trades at $27.97, showing modest daily gains but facing bearish technical signals with the current price near key support levels. The company demonstrates improving fundamentals with revenue growth from $2.2B in 2024 to $2.6B in 2025 and a return to profitability, though valuation metrics remain elevated with a P/E of 121.57. Recent developments include AI integration initiatives and resolution of FTC litigation, while the housing market faces affordability challenges.

The stock presents a mixed outlook with analyst consensus pointing to significant upside potential (average target $52) but near-term headwinds from housing market volatility. Investment opportunity lies in Zillow's platform transition and market leadership, balanced against risks from mortgage rate sensitivity and competitive pressures. The current price near 52-week lows may offer entry points for long-term investors believing in the housing tech transformation story.